Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Nivolumab in combination with ipilimumab, is indicated for the treatment of patients with intermediate/poor risk advanced renal cell carcinoma (RCC)
Registration date